Primary care-led weight-management intervention: qualitative insights into patient experiences at one-year follow up

Figures & data

Table I. Programme layout of the NHS primary care weight management intervention.

Programme	Option 1	Option 2	Option 3
Phases	3	2	2
Duration	Meal Replacement: 8–12 weeks Lifestyle and behaviour change programme: 12 weeks Ongoing support: up to 2 years	Lifestyle and behaviour change programme including partial meal-replacement utilization: 12 weeks Ongoing support: up to 2 years	Lifestyle and behaviour change programme: 12 weeks Ongoing support: up to 2 years
Support	Weekly phone consultations with registered nutritionist during meal replacement phase: Week 1–4 Weekly message check-in on app with registered nutritionist: Week 5–8/12 Weekly phone consultations with registered nutritionist during transition, lifestyle and behaviour change phase: Week 8/12–12/16 Fortnightly message check-in on app with registered nutritionist: up to 2 years	Weekly phone consultations with registered nutritionist: Week 1–4 Fortnightly message check-in on app with registered nutritionist: up to 2 years	Weekly phone consultations with registered nutritionist: Week 1–4 Fortnightly message check-in on app with registered nutritionist: up to 2 years

Table II. Participant characteristics at baseline.

#	Gender	Ethnicity	Age	BMI Start	Programme	% weight loss	Co-morbidities Start	Medications Start
1	female	White	45	42.6	Combi 3	−1	IBS, gallstones, chronic pancreatitis, GORD	Omeprazole (GORD)
2	female	White	34	36.6	Combi 3	10	Infertility, chronic knee pain	None
3	male	Black	46	30.6	Fast 4	16	T2D, hypertension, hypercholesterolemia	Atorvastatin (hypercholesterolemia), amlodipine (hypertension)
4	male	Asian	42	33.8	Fast 4	15	T2D, hypertension	Metformin (T2D), losartan (hypertension)
5	female	White	45	28.7	Combi 3	13	Depression	Prozac (depression)
6	male	Black	36	32.1	Combi 3	6	Severe sleep apnoea	CPAP machine (sleep apnoea)
7	male	Black	35	33.5	Combi 3	10	Severe GI complications	None
8	female	Black	62	40.5	Fast 4	12	T2D, hypertension, hypercholesterolemia, arthritis	Metformin (T2D), atorvastatin (hypercholesterolemia), furosemide (hypertension)
9	female	White	67	31.2	Combi 3	15	Colon cancer, hypertension, asthma	Beloc zok cor (hypertension), symbicort inhaler (asthma)
10	male	White	72	27.7	Combi 3	18	Hypercholesterolemia, asthma, arthritis	Simvastatin (hypercholesterolemia), symbicort inhaler (asthma)
11	female	Black	56	29	Combi 3	17	Hypertension	None
12	female	Asian	43	29.4	Fast 4	13	T2D, Gastritis, Hypertension, IBS	Metformin (T2D), losartan (hypertension)
13	female	White	34	43.3	Combi 3	1	Depression, anxiety, arthritis	None
14	female	Asian	47	36.1	Fast 4	17	Prediabetes, GORD	None
15	male	Black	56	48.4	Fast 4	2	T2D, hypertension, COPD	Metformin (T2D), atorvastatin (hypercholesterolemia), doxazosin (hypertension), losartan (hypertension), aspirin (blood clots), amlodipine (hypertension)
16	female	White	42	36.6	Combi 3	31	none	None
17	male	White	46	39.8	Combi 3	13	asthma	Symbicort inhaler (asthma)
18	female	White	69	29	Fast 4	9	T2D, hypertension, arthritis, GORD	Metformin (T2D), Omeprazole (GORD), felodipine (hypertension), naproxen (arthritis)
19	male	White	68	44.2	Combi 3	21	GORD, arthritis, hypertension	Lansoprazole (GORD), Ibuprofen (arthritis), amlodipine (hypertension)
20	female	White	39	44	Combi 3	−1	PCOS, hypertension, depression	Metformin (PCOS)
21	female	Asian	37	37.6	Combi 3	8	PCOS, hypertension, IBS	Metformin (PCOS), ramipril (hypertension)
	13F, 8M	11W, 4A, 6B	34–72	29–48.4	7 F4, 14 C3

Table III. Participant characteristics after 1 year.

#	Gender	Ethnicity	Age	BMI Y1	Kg Start	Kg Y1	% weight loss	Co-morbidities Now	Medications Now
1	female	White	45	42.9	119	120	−1	IBS, gallstones, chronic pancreatitis, GORD	Omeprazole (GORD)
2	female	White	34	32.9	106	95	10	Infertility, chronic knee pain	None
3	male	Black	46	25.6	96	81	16	T2D, hypertension, hypercholesterolemia	Atorvastatin (hypercholesterolemia), amlodipine (hypertension)
4	male	Asian	42	28.8	100	85.1	15	T2D	None
5	female	White	45	24.9	83	72	13	Depression	Prozac (depression)
6	male	Black	36	30.2	116.6	109.7	6	Medium sleep apnoea	CPAP machine (sleep apnoea)
7	male	Black	35	30	106.1	95	10	Mild GI complications	None
8	female	Black	62	35.6	107	94	12	Hypertension, arthritis	Furosemide (hypertension)
9	female	White	67	27.1	82	70	15	Colon cancer, asthma	Symbicort inhaler (asthma)
10	male	White	72	23.4	84.2	69	18	Hypercholesterolemia, asthma, arthritis	Simvastatin (hypercholesterolemia), symbicort inhaler (asthma)
11	female	Black	56	24.2	84	70	17	Hypertension, gastritis	None
12	female	Asian	43	25.5	74.5	64.5	13	Prediabetes, hypertension	Metformin (prediabetes), losartan (hypertension)
13	female	White	34	43	111	110	1	Depression, anxiety, arthritis	None
14	female	Asian	47	29.9	77	63.7	17	GORD	None
15	male	Black	56	47.3	136	133	2	T2D, hypertension, COPD	Metformin (T2D), atorvastatin (hypercholesterolemia), doxazosin (hypertension), losartan (hypertension), aspirin (blood clots), amlodipine (hypertension)
16	female	White	42	25.4	101	70	31	none	none
17	male	White	46	32.1	120	104.4	13	asthma	Symbicort inhaler (asthma)
18	female	White	69	26.2	69	63	9	Hypertension	Felodipine (hypertension), naproxen (arthritis)
19	male	White	68	34.5	138	109	21	Arthritis	Ibuprofen (arthritis)
20	female	White	39	44.5	103	104.5	−1	PCOS, hypertension, depression	Metformin (PCOS)
21	female	Asian	37	34.9	94.1	87	8	PCOS, hypertension, IBS	Metformin (PCOS), ramipril (hypertension)
	13F, 8M	11W, 4A, 6B	34–72	23.4–47.3	69–138	63–133

Table IV. Participant weight loss % year 1.

Successful weight loss was defined as having achieved >10% intentional weight loss at Year 1.

Table V. Weight loss targets and achievements.

Figure 1. The experiences of weight management.